ADMA
ADMA Biologics, Inc.
ADMA's fundamentals are strong: its operating margin rose 12 points to 46% and it turned 26% of its revenue into free cash flow. At 17x earnings, it's trading below its usual 21x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ADMA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
ADMA's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ADMA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $10.76 | -19% |
| Forward | 16x | $13.24 | — |
| Current | 17x | $13.24 | — |
| Fair | 21x | $16.22 | +23% |
| Expensive | 66x | $50.55 | +282% |
Historical ranges are pointers, not guarantees.
ADMA's PE is in its cheap range at 17x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ADMA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
ADMA has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ADMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.81 | +5.6% |
| Q3 2026 | $0.77 | -9.4% |
| Q2 2026 | $0.70 | -18% |
| Q1 2026 | $0.68 | -19% |
| Q4 2025 | $0.60 | -26% |
| Q3 2025 | $0.85 | +204% |
| Q2 2025 | $0.85 | +507% |
| Q1 2025 | $0.84 | +$0.86 |
| Q4 2024 | $0.81 | +$0.94 |
ADMA has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ADMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $141.1M | +5.1% |
| Q2 2026 | $124.4M | +2% |
| Q1 2026 | $114.5M | -0.3% |
| Q4 2025 | $139.2M | +18% |
| Q3 2025 | $134.2M | +12% |
| Q2 2025 | $122M | +14% |
| Q1 2025 | $114.8M | +40% |
| Q4 2024 | $117.5M | +59% |
ADMA's revenue is growing: $141M last quarter, up 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 48% | +10 points |
| Q2 2026 | 42% | +7.1 points |
| Q1 2026 | 51% | +21 points |
| Q4 2025 | 45% | +13 points |
| Q3 2025 | 38% | +4.9 points |
| Q2 2025 | 35% | -1.5 points |
| Q1 2025 | 30% | +3.7 points |
| Q4 2024 | 33% | +13 points |
ADMA has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ADMA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ADMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.4M | +$16.4M |
| Q2 2026 | $27.3M | +46% |
| Q1 2026 | $55.7M | +$80.1M |
| Q4 2025 | $34.6M | -27% |
| Q3 2025 | -$1.1M | -104% |
| Q2 2025 | $18.7M | -57% |
| Q1 2025 | -$24.4M | -$19.8M |
| Q4 2024 | $47.5M | +189% |
ADMA has burned cash in most quarters: $133M over the past year, about three times what it generated the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ADMA on cash flow, with more consistent year-over-year improvement.
ADMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -4.5M shares |
| 1 year | -7.7% | -18.8M shares |
| 3 years | -3.4% | -7.9M shares |
| 5 years | +77% | +98.4M shares |
| Available history | +206% | +152M shares |
ADMA has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $25.1M |
| Q2 2026 | $25.1M |
| Q1 2026 | $130.2M |
| Q4 2025 | $8.9M |
ADMA spent $189M buying back its own shares over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ADMA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
ADMA's net debt is less than a year of its operating earnings (EBITDA).
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ADMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.1 | Neutral |
| Stochastic | 85.4 | Overbought |
ADMA's weekly RSI is 69 (neutral) and its Stochastic is 85 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ADMA PE vs Healthcare Sector
| Metric | ADMA | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 28 | 29 | 1 pt below |
ADMA is trading at 17x earnings, a 34% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ADMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.0 | 20% above |
| 20 week MA | $9.91 | 34% above |
| 50 week MA | $12.0 | 10% above |
| 100 week MA | $14.9 | 11% below |
| 200 week MA | $11.4 | 17% above |
ADMA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ADMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.95 | $2.15 | -46% |
| 2021 | $2.15 | $1.27 | -41% |
| 2022 | $1.27 | $3.65 | +187% |
| 2023 | $3.65 | $4.52 | +24% |
| 2024 | $4.52 | $17.5 | +286% |
| 2025 | $17.5 | $19.3 | +10% |
| 2026 YTD | $19.3 | $13.2 | -31% |
ADMA has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.